Genetic testing to identify high-risk populations for chemoprevention studies

Issue title: Selected Papers from the 2nd Haifa Cancer Prevention Workshop, 4–6 May 2006

Guest editors: D.E. Brennerx and G. Rennerty

Article type: Research Article

Authors: Velasquez, Jonathan L.^{; *} | Lipkin, Steven M.

Affiliations: Departments of Medicine, Divisions of Hematology-Oncology and Epidemiology, University of California, 839 Medical Sciences Court, 2nd Floor, Sprague Hall – Lab 250, Irvine, CA 92697, USA | [x] University of Michigan Medical Center, Ann Arbor, MI 48109-0930, USA | [y] CHS National Cancer Control Center, Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion Haifa, Israel

Correspondence: [*] Corresponding author. Tel.: +1 949 824 9221; Fax: +1 949 824 4405; E-mail: [email protected], [email protected].

Abstract: Human genetic variation data is now publicly available on a large scale, from both public and private discovery efforts. Datasets from the International Haplotype Map Consortium and Perlegen Sciences provide a level of knowledge about human genetic variation that is unprecedented. In combination with novel high-throughput genotyping technologies, these new resources will allow cancer prevention investigators to identify in a more precise way which genetic subsets of patients are likely to benefit most from chemoprevention and screening interventions.

Keywords: SNPs, haplotypes, chemoprevention

DOI: 10.3233/CBM-2007-3307

Journal: Cancer Biomarkers, vol. 3, no. 3, pp. 163-168, 2007